Enterprise Value
158.6M
Cash
19.4M
Avg Qtr Burn
-436K
Short % of Float
6.95%
Insider Ownership
1.21%
Institutional Own.
55.53%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Onivyde® (irinotecan liposome injection) + 5 fluorouracil/leucovorin+ oxaliplatin Details Pancreatic cancer, Cancer | sNDA Submission | |
Onivyde® (irinotecan liposome injection) Details Cancer, Small cell lung cancer, Lung cancer | Phase 3 Data readout |